<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088773</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0677</org_study_id>
    <nct_id>NCT04088773</nct_id>
  </id_info>
  <brief_title>Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease</brief_title>
  <official_title>Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leona M. and Harry B. Helmsley Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will evaluate if specific blood, stool and MRI tests can tell the
      difference between bowel wall inflammation without scarring and bowel wall inflammation with
      scarring that can cause bowel blockages requiring surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center study will test the accuracy of individual and combined MRI and blood-based
      diagnostic tools in both children and adults with small bowel CD. We will determine the
      accuracy of a composite tool (including its multiple individual biomarkers) for defining the
      relative amounts of intestinal inflammation versus scarring in patients at the time of
      surgery (B2 disease) and in patients at an early stage of disease prior to complications (B1
      disease).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Magnetization transfer ratio (MTR)</measure>
    <time_frame>Day 1</time_frame>
    <description>compare MTR values between Aim 1 and Aim 2 cohorts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between MTR values and bowel wall collagen measurements</measure>
    <time_frame>Day 1</time_frame>
    <description>combine all subjects from Aim 1 and Aim 2 that undergo MRI</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Aim 1 Crohn Disease participants (B2 phenotype)</arm_group_label>
    <description>Crohn's Disease participants scheduled for ileal small bowel resection; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim 2 Crohn Disease participants (B1 phenotype)</arm_group_label>
    <description>Crohn's Disease participants with uncomplicated small bowel disease; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim 2 Healthy Controls</arm_group_label>
    <description>No intervention; observational only; collection of blood, stool, and completion of Gastrointestinal Symptoms Rating Scale</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood biomarkers</intervention_name>
    <description>biomarkers to distinguish fibrotic vs non-fibrotic CD lesions</description>
    <arm_group_label>Aim 1 Crohn Disease participants (B2 phenotype)</arm_group_label>
    <arm_group_label>Aim 2 Crohn Disease participants (B1 phenotype)</arm_group_label>
    <arm_group_label>Aim 2 Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>stool biomarkers</intervention_name>
    <description>fecal biomarkers of inflammation, mucosal inflammation</description>
    <arm_group_label>Aim 1 Crohn Disease participants (B2 phenotype)</arm_group_label>
    <arm_group_label>Aim 2 Crohn Disease participants (B1 phenotype)</arm_group_label>
    <arm_group_label>Aim 2 Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI imaging</intervention_name>
    <description>MRI imaging to detect bowel wall fibrosis and to detect inflamed, non-fibrotic from inflamed, fibrotic bowel</description>
    <arm_group_label>Aim 1 Crohn Disease participants (B2 phenotype)</arm_group_label>
    <arm_group_label>Aim 2 Crohn Disease participants (B1 phenotype)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Aim 1 - Children and adults undergoing surgical small bowel resection for structuring CD;
        Aim 2 - children and adults that have known uncomplicated inflammatory small bowel CD
        (B1phenotype) AND healthy non-IBD participants
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aim 1 (CD participants)

               1. Aged 8-70 years

               2. Undergoing first surgical distal (ileal) small bowel resection for structuring
                  (B2 phenotype) Crohn's disease as determined by CTE or MRE or ileocolonoscopy

               3. English speaking

          -  Aim 2 (CD participants)

               1. Age 8 to 70 years

               2. Uncomplicated inflammatory small bowel CD based on clinical CTE or MRE or
                  ileocolonoscopy performed within 6 months prior to enrollment (CD participants
                  only)

               3. English speaking

          -  Aim 2 (Control participants)

               1. Age 8 to 70 years

               2. English speaking

        Exclusion Criteria:

          -  Aim1 (CD participants)

               1. B1 or B3 (i.e., fistula, abscess, phlegmon/inflammatory mass) CD phenotype

               2. Prior small bowel surgery, including but not limited to surgical resection,
                  stricturoplasty, or endoscopic treatment of a small bowel stricture

               3. Anything to eat or drink within 4 hours of study visit (participants may take
                  their required medications with a little water)

               4. Known pregnancy (Note: Institutional policies/procedures will be followed for
                  pregnancy screening)

               5. Contraindication for MRI (e.g., surgical implant, claustrophobia). Note: To be
                  determined based on local procedures.

          -  Aim 2 (CD participants)

               1. Stenotic ileocecal valve at colonoscopy

               2. Prior small bowel surgery, including but not limited to surgical resection,
                  stricturoplasty, or endoscopic treatment of a small bowel stricture

               3. Anything to eat or drink within 4 hours of study visit (participants may take
                  their required medications with a little water)

               4. Known pregnancy (Note: Institutional policies/procedures will be followed for
                  pregnancy screening)

               5. Contraindication for MRI (e.g., surgical implant, claustrophobia). Note: To be
                  determined based on local procedures.

          -  Aim 2 (Control participants)

               1. Any known gastrointestinal tract disease

               2. Any known inflammatory/autoimmune disease involving another organ system (e.g.,
                  rheumatoid arthritis, scleroderma, multiple sclerosis).

               3. Fecal calprotectin level of Ëƒ100 mcg.gm will be excluded from further analysis
                  and replaced.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Dillman, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Becky Imbus</last_name>
    <phone>513-636-9403</phone>
    <email>rebecca.imbus@cchmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory/Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <email>holoyed@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Subra Kugathasan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <email>ilajm@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Stidham, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14625</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <email>becker.brenda1@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>David Bruining, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <email>rebecca.imbus@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Dillman, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

